Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05140967
Other study ID # ABW-2021-CF
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 15, 2021
Est. completion date December 2024

Study information

Verified date June 2024
Source University of Kiel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim of the randomized controlled trial is to investigate the effects of endurance training with different intensities on physical performance, body composition and appetite regulation in people with cystic fibrosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - confirmed diagnosis of cystic fibrosis by at least 2 sweat tests and / or by the presence of two CF mutations, - willingness to participate in and to comply with the research project procedure, - written informed consent of patients, - age = 18 years, - FEV1 of pred. = 40%, - Stable condition (as indicated by absence of one or more signs: new or increased haemoptysis, increased malaise, fatigue or lethargy, temperature over 38°C, weight loss, sinus pain and a decrease in pulmonary function by 10% or more) Exclusion Criteria: - Severe pulmonary exacerbation, - cor pulmonale, - musculoskeletal discomfort that makes a regular exercise training impossible, - untreated CF-related diabetes

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High Intensity Interval Training (HIIT)
High Intensity Interval Training
Moderate Continuous Intensity Training (MICT)
Moderate Intensity Continuous Training

Locations

Country Name City State
Germany Fachklink Satteldüne der DRV Nord Nebel / Amrum Schleswig-Holstein
Germany Strandklinik St. Peter-Ording Saint Peter-Ording Schleswig-Holstein

Sponsors (4)

Lead Sponsor Collaborator
University of Kiel Fachklinik Satteldüne der DRV Nord, Strandklinik St. Peter-Ording, University of Kiel, Arbeitsbereich Sportmedizin und Trainingswissenschaften

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in Peak Oxygen Uptake measured with peak Oxygen uptake (VO2) in percent predicted at baseline and after 4 weeks of exercise training program
Primary change in Peak Workload measured with peak Workload in percent predicted at baseline and after 4 weeks of exercise training program
Primary change body fat mass index measured with body fat mass index (FMI) in kg / m*2 at baseline and after 4 weeks of exercise training program
Primary change in Body fat free mass index measured with fat free body mass index (FFMI) in kg / m*2 at baseline and after 4 weeks of exercise training program
Secondary change in Forced Expiratory Volume in 1 second measured with Forced Expiratory Volume in 1 second (FEV1) in percent predicted at baseline and after 4 weeks of exercise training program
Secondary change in Health related quality of life measured with the Cystic Fibrosis Questionnaire Revised (CFQ-R); 9 Quality of life domains: Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions: 3 symptom scales: Weight, respiratory, and digestion Scores range from 0 to 100, with higher scores indicating better health. at baseline and six and twelve months after completion of exercise training program
Secondary appetite control - subjective feeling of hunger measured with visual analogue scales. The scale consists of a 10 cm vertical line anchored with "not hungry at all" at the left side and with "extremely hungry" at the right side. at baseline and after 4 weeks of exercise training program
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A